Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value
$11.37−0.13 (-1.09%)
Close on Nov 13, 2026Market cap $695.13MP/E –Yield –
Janux Therapeutics cash
Cash and short-term investments held at the end of each period.
Janux Therapeutics's cash was $945.72M at Sep 30, 2026. For fiscal 2025 it was $966.57M, down 5.7% from the year before. The highest annual figure on record is $1.03B in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $966.57M | -5.7% |
| FY2024 | Dec 31, 2024 | $1.03B | +198.0% |
| FY2023 | Dec 31, 2023 | $344.03M | +5.2% |
| FY2022 | Dec 31, 2022 | $327.02M | -12.8% |
| FY2021 | Dec 31, 2021 | $374.97M | +4699.2% |
| FY2020 | Dec 31, 2020 | $7.81M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $945.72M | -4.4% |
| Q2 FY2026 | Jun 30, 2026 | $970.91M | -2.5% |
| Q1 FY2026 | Mar 31, 2026 | $956.39M | -5.7% |
| Q4 FY2025 | Dec 31, 2025 | $966.57M | -5.7% |
| Q3 FY2025 | Sep 30, 2025 | $988.99M | +50.3% |
| Q2 FY2025 | Jun 30, 2025 | $996.01M | +54.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.01B | +55.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.03B | +198.0% |
| Q3 FY2024 | Sep 30, 2024 | $658.03M | +88.2% |
| Q2 FY2024 | Jun 30, 2024 | $646.29M | +113.1% |
| Q1 FY2024 | Mar 31, 2024 | $651.76M | +105.7% |
| Q4 FY2023 | Dec 31, 2023 | $344.03M | +5.2% |
| Q3 FY2023 | Sep 30, 2023 | $349.71M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | $303.29M | -14.4% |
| Q1 FY2023 | Mar 31, 2023 | $316.88M | -12.3% |
| Q4 FY2022 | Dec 31, 2022 | $327.02M | -12.8% |
| Q3 FY2022 | Sep 30, 2022 | $338.76M | -12.6% |
| Q2 FY2022 | Jun 30, 2022 | $354.30M | -10.1% |
| Q1 FY2022 | Mar 31, 2022 | $361.20M | +4523.1% |
| Q4 FY2021 | Dec 31, 2021 | $374.97M | – |
| Q3 FY2021 | Sep 30, 2021 | $387.51M | – |
| Q2 FY2021 | Jun 30, 2021 | $394.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.81M | – |
See a number that looks wrong?